RealTime Software Solutions Announces Acquisition of Devana Solutions
RealTime Software Solutions has announced its acquisition of Devana Solutions, an SaaS provider specializing in clinical trial workflow and analytics solutions.
By integrating Devana's solutions into RealTime's Site Operations Management System (SOMS), clinical research organizations will be able to access a suite of capabilities that bridge centralized operations with site-based clinical teams. The combination of these solutions establishes connectivity between Devana's business development and data analytics platform and RealTime's suite of products that includes CTMS, eRegulatory solutions, eSource, eConsent, payments, texting solutions, the MyStudyManager Participant Portal, and other eClinical solutions and services.
Originally designed to address the operational gap before participant recruitment, screening and CTMS-managed clinical workflows, Devana's PROPEL products automate pipeline management and trial startup workflows while capturing timing and performance metrics for analysis and action.
Reference
RealTime Software Solutions Strengthens its Position in the Clinical Research Industry with the Acquisition of Devana Solutions. (2023, July 6). Cision PR Newswire.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
